Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70 in BRCAMutated Ovarian Cancer in Phase 3 Trial

Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in BRCA-Mutated Ovarian Cancer in Phase 3 Trial

KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced detailed results from the Phase 3 SOLO-1 trial testing LYNPARZA 300 mg tablets twice daily as a maintenance treatment for patients with newly-diagnosed advanced BRCA-mutated (BRCAm) ovarian cancer who were in complete or partial response following first-line standard platinum-based …

More From BioPortfolio on "Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in BRCA-Mutated Ovarian Cancer in Phase 3 Trial"